No profile data available.
Stereotaxis, Inc. (STXS) is a healthcare company in the heart treatment equipment industry, based in Saint Louis, United States, with about 131 full-time employees.
It reported revenue of $26.92 million for fiscal year 2024, up 0.5% from fiscal year 2023, and net income of -$25.35 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $7.46 million, down 18.8% from a year before. International was its largest region in fiscal year 2025, with 60% of revenue. Its market capitalization was $111.22 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Stereotaxis reported $26.92 million in revenue for fiscal year 2024, up 0.5% from $26.77 million in fiscal year 2023. In Q3 2025 revenue was $7.46 million.
International: 60% of revenue by region in fiscal year 2025, followed by United States (40%).
$111.22 million as of October 8, 2026.
Listed companies of a similar size in the same industry (heart treatment equipment) include Orchestra BioMed Holdings, Inc. (OBIO), Picard Medical, Inc. (PMI), Anteris Technologies Global Corp. (AVR), Streamex Corp. (STEX).